Skip to main content

Aro Biotherapeutics

Philadelphia, United States

Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.

$41.5M raised
Nov 2023
Series B

Top Investors

HealthCapIonis PharmaceuticalsJohnson & Johnson Innovation JJDCNorthpond VenturesCowen Healthcare Investments

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Aro Biotherapeutics

How much funding has Aro Biotherapeutics raised?
Aro Biotherapeutics has raised $41.5M in total funding. The most recent round was Series B. The last funding was announced in November 2023.
Who are Aro Biotherapeutics's investors?
Aro Biotherapeutics's investors include HealthCap, Ionis Pharmaceuticals, Johnson & Johnson Innovation JJDC, Northpond Ventures, Cowen Healthcare Investments.
Where is Aro Biotherapeutics headquartered?
Aro Biotherapeutics is headquartered in Philadelphia, United States.
What does Aro Biotherapeutics do?
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
What stage is Aro Biotherapeutics at?
Aro Biotherapeutics is at the Series B stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Aro Biotherapeutics — Funding & Investors." VCBacked, November 28, 2023, https://www.vcbacked.co/company/aro-biotherapeutics. Accessed June 17, 2026.
APA
VCBacked. (2023). Aro Biotherapeutics — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/aro-biotherapeutics
Wikipedia (cite web)
{{cite web |title=Aro Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aro-biotherapeutics |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .